US 12,077,775 B2
Effector proteins and methods of use
Aaron Deloughery, San Francisco, CA (US); Matan Drory Retwitzer, Foster City, CA (US); Lucas Benjamin Harrington, San Francisco, CA (US); Wiputra Jaya Hartono, San Francisco, CA (US); Alexander Richard Neckelmann, San Francisco, CA (US); David Paez-Espino, Concord, CA (US); Benjamin Julius Rauch, San Francisco, CA (US); Clarissa Oriel Rhines, San Mateo, CA (US); Stepan Tymoshenko, Sacramento, CA (US); Fnu Yunanda, Daly City, CA (US); and William Douglass Wright, Fairfield, CA (US)
Assigned to Mammoth Biosciences, Inc., Brisbane, CA (US)
Filed by Mammoth Biosciences, Inc., Brisbane, CA (US)
Filed on Jun. 12, 2023, as Appl. No. 18/333,467.
Application 18/333,467 is a continuation of application No. PCT/US2023/061022, filed on Jan. 20, 2023.
Claims priority of provisional application 63/386,144, filed on Dec. 5, 2022.
Claims priority of provisional application 63/381,282, filed on Oct. 27, 2022.
Claims priority of provisional application 63/371,502, filed on Aug. 15, 2022.
Claims priority of provisional application 63/346,244, filed on May 26, 2022.
Claims priority of provisional application 63/334,663, filed on Apr. 25, 2022.
Claims priority of provisional application 63/301,963, filed on Jan. 21, 2022.
Prior Publication US 2023/0323406 A1, Oct. 12, 2023
Int. Cl. C12N 9/22 (2006.01); C12N 15/00 (2006.01); C12N 15/11 (2006.01); C12N 15/86 (2006.01); C12N 15/90 (2006.01)
CPC C12N 15/907 (2013.01) [C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/86 (2013.01); C12N 2750/14143 (2013.01)] 30 Claims
OG exemplary drawing
 
1. A composition comprising:
a) an engineered polypeptide or a nucleic acid encoding the engineered polypeptide, wherein the engineered polypeptide comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 1, and wherein the engineered polypeptide comprises at least one amino acid substitution relative to SEQ ID NO: 1; and
b) a guide nucleic acid comprising a first sequence and a second sequence,
wherein the engineered polypeptide is capable of binding the first sequence, and wherein the first sequence and the second sequence are heterologous, and
wherein the at least one amino acid substitution is selected from K58W, I80R, T84R, K105R, N193K, C202R, S209F, G210R, A218R, A218K, D220R, E225R, E225K, D237A, C246R, N286K, M298L, A306K, Y315M, E335A, E335Q, Q360R, D418A, and D418N.